New model for Lonza

Lonza has revealed that its “simplified and streamlined operating model” is now effective. Originally announced in at its investor update in December 2024, the Lonza Engine is part of the One Lonza strateg and seeks to “bring together the company’s unique core competencies that enable outstanding value creation”.

The number of CDMO business platforms has been reduced to three with the business unit layer removed. The Capsules & Health Ingredients business will continue to operate in its existing structure until it is sold as part of Lonza’s transformation into a pure-play CDMO. Those remaining are: 

• Integrated Biologics, led by Gordon Bates, comprising mammalian and drug product services
• Advanced Synthesis (Christian Seufert), combining the former Small Molecules division and bioconjugates
• Specialized Modalities (Daniel Palmacci), with cell and gene technologies, mRNA, microbial and bioscience activities

Each is directly managing multiple technology platforms and each is said to have five key components: high performance teams; a strong scientific, technological and digital ecosystem; strong customer partnerships; end-to-end execution excellence; and plug-and-play investment and integration capabilities.